• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Sangart

edit

Sangart, Inc. is a privately held biopharmaceutical company focused on being the global scientific, clinical and commercial leader in oxygen-therapeutic agents, providing innovative products to patients in need. Sangart was founded in 1998 based on discoveries arising from over two decades of research in red blood cell substitutes and the mechanisms of oxygen transport by cell-free hemoglobin solutions.

Milestones

edit

• 
  Sangart received $50M in Series G funding. (5/24/12)
  Posted 5/24/12 at 9:43pm via finsmes.com
• 
  Sangart received $50M in Venture Round funding. (4/19/11)
  Posted 4/19/11 at 6:06pm via sangart.com
• 
  Sangart received $100M in Series F funding. (3/12/09)
  Posted 3/13/09 at 10:46am via pehub.com

Videos

Screenshots

edit

Traffic Analytics

Compete

Sources

1. Artificial Blood Substitute Maker Raises $50 Million (pehub.com) [edit]
2. SANGART ANNOUNCES CLOSING OF $50 MILLION SERIES G FINANCING (sangart.com) [edit]
3. Sangart Raises $50M in Series G Equity Funding (finsmes.com) [edit]